FDA's Accelerated Pathways Are The New Normal

August 23, 2017

In order to better understand how major US payers view AP products, PAREXEL and the nonprofit, non-partisan Network for Excellence in Healthcare Innovation (NEHI), conducted a survey of 20
national, regional, public, and private payers whose coverage decisions impact a total of 228 million patients.  Read the results in this article.

Previous Flipbook
Regulatory Handbook: Data Integrity: FDA And Global Regulatory Guidance
Regulatory Handbook: Data Integrity: FDA And Global Regulatory Guidance

Learn the newest trends and regulatory changes as we guide you through FDA and global regulations, guidance...

Next Flipbook
Smart Strategies for the Beginning and End of Drug Development
Smart Strategies for the Beginning and End of Drug Development